Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488724 | 0.93 | KIT (0.51) | KITBRAF | |
| SCHEMBL1489032 | 0.92 | KIT (0.49) | KITBRAF | |
| SCHEMBL1488398 | 0.91 | KIT (0.51) | KITBRAF | |
| SCHEMBL1488386 | 0.88 | KIT (0.50) | KITBRAF | |
| SCHEMBL14040219 | 0.84 | NOTUM (0.43) | KITBRAF | |
| SCHEMBL5178265 | 0.83 | KIT (0.47) | KITBRAF | |
| SCHEMBL13714564 | 0.82 | KIT (0.49) | KITBRAF | |
| SCHEMBL3873766 | 0.82 | KIT (0.59) | KITBRAF | |
| SCHEMBL1488991 | 0.82 | NOTUM (0.48) | KITBRAF | |
| SCHEMBL3875110 | 0.81 | KIT (0.61) | KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | claimed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | claimed |
| WO-2008119569-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | claimed |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AG (DE) | 2008-10-02 | — | — | US | claimed |
| EP-1975166-A1 | Synthesis of anthranilamides | Bayer Schering Pharma AG (DE) | 2008-10-01 | — | — | EP | claimed |
| EP-1807413-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | claimed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | claimed |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-06-01 | — | — | US | claimed |
| WO-2006048251-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | claimed |
| EP-1655295-A1 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-10 | — | — | EP | claimed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | disclosed |
| WO-2008119569-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| EP-1975166-A1 | Synthesis of anthranilamides | Bayer Schering Pharma AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1807413-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006048251-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655295-A1 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | KIT 43/4885BRAF 172/4885 |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | KIT 127/4885BRAF 178/4885 |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | FLT1, KDR, FLT4 | KIT 43/4885BRAF 172/4885 |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | ANTXR2, QTRT1, NQO2 | KIT 2988/4885BRAF 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.